Do monogenic inborn errors of immunity cause susceptibility to severe COVID-19?


Journal

The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877

Informations de publication

Date de publication:
15 07 2021
Historique:
pubmed: 2 6 2021
medline: 20 7 2021
entrez: 1 6 2021
Statut: ppublish

Résumé

The SARS-CoV-2 virus, which causes COVID-19, has been associated globally with substantial morbidity and mortality. Numerous reports over the past year have described the clinical and immunological profiles of COVID-19 patients, and while some trends have emerged for risk stratification, they do not provide a complete picture. Therefore, efforts are ongoing to identify genetic susceptibility factors of severe disease. In this issue of the JCI, Povysil et al. performed a large, multiple-country study, sequencing genomes from patients with mild and severe COVID-19, along with population controls. Contrary to previous reports, the authors observed no enrichment of predicted loss-of-function variants in genes in the type I interferon pathway, which might predispose to severe disease. These studies suggest that more evidence is needed to substantiate the hypothesis for a genetic immune predisposition to severe COVID-19, and highlights the importance of considering experimental design when implicating a monogenic basis for severe disease.

Identifiants

pubmed: 34061775
pii: e149459
doi: 10.1172/JCI149459
pmc: PMC8279660
doi:
pii:

Substances chimiques

Interferon Type I 0

Types de publication

Journal Article Comment

Langues

eng

Sous-ensembles de citation

IM

Commentaires et corrections

Type : CommentOn

Références

J Clin Immunol. 2020 Jan;40(1):24-64
pubmed: 31953710
Am J Psychiatry. 2019 May 1;176(5):376-387
pubmed: 30845820
J Mol Diagn. 2017 Jan;19(1):4-23
pubmed: 27993330
J Clin Immunol. 2021 Apr;41(3):666-679
pubmed: 33598806
J Clin Invest. 2021 Jul 15;131(14):
pubmed: 34061776
Nature. 2007 Jun 7;447(7145):655-60
pubmed: 17554299
Nature. 2020 May;581(7809):434-443
pubmed: 32461654
Science. 2020 Oct 23;370(6515):
pubmed: 32972995
J Clin Invest. 2021 Jul 15;131(14):
pubmed: 34043590
Science. 2020 Oct 23;370(6515):
pubmed: 32972996
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
J Allergy Clin Immunol. 2021 Feb;147(2):520-531
pubmed: 32980424
Nat Rev Immunol. 2021 Apr;21(4):245-256
pubmed: 33723416
Nat Rev Immunol. 2020 Jul;20(7):442-447
pubmed: 32528136
Nature. 2020 Dec;588(7837):315-320
pubmed: 32846427
Intensive Care Med. 2021 Jun;47(6):704-706
pubmed: 33835207
J Exp Med. 2021 Jul 5;218(7):
pubmed: 33890986
Nature. 2020 Nov;587(7834):374-376
pubmed: 33139913
J Clin Immunol. 2021 Feb;41(2):345-355
pubmed: 33263173
Science. 2020 Aug 7;369(6504):718-724
pubmed: 32661059

Auteurs

Chris Cotsapas (C)

Yale University School of Medicine, New Haven, Connecticut, USA.
The Broad Institute, Cambridge, Massachusetts, USA.

Janna Saarela (J)

Center for Molecular Medicine, University of Oslo, Oslo, Norway.

Jocelyn R Farmer (JR)

Massachusetts General Hospital, Boston, Massachusetts, USA.

Vinod Scaria (V)

CSIR Institute of Genomics and Integrative Biology, New Delhi, India.

Roshini S Abraham (RS)

Department of Pathology and Laboratory Medicine, Nationwide Children's Hospital, Columbus, Ohio, USA.
The Ohio State University Wexner College of Medicine, Columbus, Ohio, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH